Now Playing
Opinion|Videos|September 30, 2024
ESMO 2024: Updates in NIAGARA Study
Panelists discuss how overall survival and event-free survival data presented at ESMO 2024 demonstrate promising outcomes in cancer treatment.
Advertisement
Advertisement
Related to this article
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
Advertisement
Advertisement
Trending on Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Late-Breaking Breast Cancer Data at ESMO 2026 Highlight ADCs and Ribociclib
3
Elranatamab Improves PFS in Relapsed/Refractory Multiple Myeloma
4
ADCs Shine, Mixed Bag for Immunotherapy at ESMO 2026 Presidential Symposium III
5